On May 23, 2025, HC Wainwright & Co. analyst Yi Chen announced a change in the price target for Kala Bio (KALA, Financial). The price target was lowered from USD 15.00 to USD 12.00. Despite this adjustment, the analyst maintains a 'Buy' rating for KALA, consistent with the previous assessment.
The revised price target represents a 20.00% decrease from the prior valuation. This update is crucial for investors tracking Kala Bio (KALA, Financial) as it reflects the analyst’s current outlook on the company's stock performance in the market.
Kala Bio (KALA, Financial), listed on NASDAQ, continues to hold a 'Buy' rating, suggesting that the stock may still present a lucrative opportunity for investors despite the reduced price target. The adjustment in the price target signifies changes in market conditions or company performance that investors should consider.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Kala Bio Inc (KALA, Financial) is $15.00 with a high estimate of $15.00 and a low estimate of $15.00. The average target implies an upside of 266.75% from the current price of $4.09. More detailed estimate data can be found on the Kala Bio Inc (KALA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Kala Bio Inc's (KALA, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
